HK1037374A1 - Pyrazole derivatives as p-38 map kinase inhibitors. - Google Patents

Pyrazole derivatives as p-38 map kinase inhibitors.

Info

Publication number
HK1037374A1
HK1037374A1 HK01108233A HK01108233A HK1037374A1 HK 1037374 A1 HK1037374 A1 HK 1037374A1 HK 01108233 A HK01108233 A HK 01108233A HK 01108233 A HK01108233 A HK 01108233A HK 1037374 A1 HK1037374 A1 HK 1037374A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
map kinase
pyrazole derivatives
methods
derivatives
Prior art date
Application number
HK01108233A
Other languages
English (en)
Inventor
Sharada Shenvi Labadie
David Mark Rotstein
Eric Brian Sjogren
Francisco Xavier Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1037374A1 publication Critical patent/HK1037374A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01108233A 1998-05-05 2001-11-22 Pyrazole derivatives as p-38 map kinase inhibitors. HK1037374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425098P 1998-05-05 1998-05-05
US12241099P 1999-03-02 1999-03-02
PCT/EP1999/002879 WO1999057101A1 (fr) 1998-05-05 1999-04-28 Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase

Publications (1)

Publication Number Publication Date
HK1037374A1 true HK1037374A1 (en) 2002-02-08

Family

ID=26770756

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108233A HK1037374A1 (en) 1998-05-05 2001-11-22 Pyrazole derivatives as p-38 map kinase inhibitors.

Country Status (23)

Country Link
EP (1) EP1075467B1 (fr)
JP (1) JP3590586B2 (fr)
KR (1) KR100404256B1 (fr)
CN (1) CN1147476C (fr)
AT (1) ATE292118T1 (fr)
AU (1) AU765030B2 (fr)
BR (1) BR9911013A (fr)
CA (1) CA2329065A1 (fr)
DE (1) DE69924480D1 (fr)
HK (1) HK1037374A1 (fr)
HR (1) HRP20000724A2 (fr)
HU (1) HUP0101581A3 (fr)
ID (1) ID27535A (fr)
IL (1) IL139169A0 (fr)
MA (1) MA26627A1 (fr)
NO (1) NO317985B1 (fr)
NZ (1) NZ507558A (fr)
PL (1) PL344004A1 (fr)
RU (1) RU2000130199A (fr)
TR (1) TR200003256T2 (fr)
TW (1) TW593282B (fr)
WO (1) WO1999057101A1 (fr)
YU (1) YU67600A (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
JP2002532415A (ja) * 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6472528B1 (en) 1999-08-10 2002-10-29 Neurocrine Biosciences, Inc. Synthesis of substituted pyrazolopyrimidines
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
DE60015599T2 (de) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
RU2299879C2 (ru) * 2000-01-17 2007-05-27 Байер Акциенгезелльшафт Замещенные арилкетоны
CA2401697A1 (fr) 2000-03-03 2001-09-07 Pfizer Products Inc. Derives d'ether de pyrazole utilises comme agents anti-inflammatoires/analgesiques
CA2408408C (fr) 2000-05-12 2013-07-09 Genzyme Corporation Modulateurs de marquage du tnf-alpha
JP5153047B2 (ja) 2000-08-17 2013-02-27 ギグオプティックス， インコーポレイテッド 電気光学用途用の最新ｎｌｏ物質の設計および合成
CZ20022642A3 (cs) * 2001-08-27 2003-09-17 Pfizer Products Inc. Způsob výroby dialkylpyridylboranů
CA2458808A1 (fr) 2001-08-30 2003-03-13 F. Hoffmann-La Roche Ag Composes d'aminopyrrole en tant qu'agents anti-inflammatoires
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EP1539121A4 (fr) 2002-08-29 2008-08-13 Scios Inc Methode pour favoriser l'osteogenese
US7294625B2 (en) 2002-09-25 2007-11-13 Ube Industries, Ltd. Pyrazole compounds
JP4838121B2 (ja) 2003-06-26 2011-12-14 ノバルティス アーゲー ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP1758579A1 (fr) * 2004-05-29 2007-03-07 7TM Pharma A/S Ligands des recepteurs crth2 a usages medicaux
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
GB0513297D0 (en) * 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2008000777A2 (fr) * 2006-06-29 2008-01-03 Glaxo Group Limited Nouveaux composés
GB0621978D0 (en) * 2006-11-03 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
CN102574836B (zh) 2009-08-07 2014-04-16 中外制药株式会社 氨基吡唑衍生物
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
JP6239118B2 (ja) * 2013-09-03 2017-11-29 サリウム リミテッド 医薬化合物
WO2015099127A1 (fr) 2013-12-27 2015-07-02 中外製薬株式会社 Gène mutant de fgfr gardien et médicament ciblant celui-ci
EP3312172B1 (fr) 2015-06-17 2020-05-06 Chugai Seiyaku Kabushiki Kaisha Dérivés d'aminopyrazole en tant qu'inhibiteurs de la kinase src
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (fr) * 2016-09-29 2018-04-05 南京明德新药研发股份有限公司 Inhibiteur de la p38α mapk kinase, son procédé de préparation et son utilisation
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
EP3563848A1 (fr) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Inhibiteurs de la serpine pour le traitement des maladies à prions et de type prion
GB201815695D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
GB201815699D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
EP3880673B1 (fr) * 2018-11-13 2024-01-03 Novartis AG Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690527B2 (en) * 1992-12-17 1998-04-30 Pfizer Inc. Pyrazoles having CRF antagonist activity

Also Published As

Publication number Publication date
JP2002513784A (ja) 2002-05-14
NZ507558A (en) 2003-08-29
EP1075467A1 (fr) 2001-02-14
NO20005535L (no) 2000-11-02
EP1075467B1 (fr) 2005-03-30
KR20010043363A (ko) 2001-05-25
ATE292118T1 (de) 2005-04-15
CN1300282A (zh) 2001-06-20
ID27535A (id) 2001-04-12
KR100404256B1 (ko) 2003-11-01
NO317985B1 (no) 2005-01-17
NO20005535D0 (no) 2000-11-02
IL139169A0 (en) 2001-11-25
PL344004A1 (en) 2001-09-10
TR200003256T2 (tr) 2001-04-20
AU765030B2 (en) 2003-09-04
HUP0101581A3 (en) 2002-07-29
BR9911013A (pt) 2001-02-06
AU4034899A (en) 1999-11-23
TW593282B (en) 2004-06-21
CN1147476C (zh) 2004-04-28
HUP0101581A2 (hu) 2002-03-28
RU2000130199A (ru) 2002-11-10
YU67600A (sh) 2003-07-07
MA26627A1 (fr) 2004-12-20
WO1999057101A1 (fr) 1999-11-11
CA2329065A1 (fr) 1999-11-11
DE69924480D1 (en) 2005-05-04
JP3590586B2 (ja) 2004-11-17
HRP20000724A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
PL344004A1 (en) Pyrazole derivatives as p-38 map kinase inhibitors
IL135302A0 (en) Bicyclic kinase inhibitors
MXPA02011320A (es) Derivados de pirazol triciclico como inhibidores de cinasa.
BR0014225A (pt) Derivados de pirazol
BG105481A (en) Tricyclic pyrazole derivatives
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
RS98804A (en) N-substituted tricyclic 3-aminopyrazoles as pdfg receptor ihhibitors
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
ATE316083T1 (de) Adamantanderivate
AU2003228770A8 (en) Substituted pyrazolopyrimidines
DE60112330D1 (en) Pyrazolopyridinderivate
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
IL145564A0 (en) Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinase
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
ECSP992945A (es) Derivados de pirazol

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080428